This manuscript aims to review the current European regulatory framework on medicine shortages. The guidance is based on a common definition of the term ‘shortages’, which should enable a more harmonised and timely approach in the detection and management of issues with the supply of medicines. Standardized reporting requirements for information on clearly defined shortages should be agreed, giving priority to critical products with high potential impact. The 35-member organisations of the European Association of Hospital Pharmacists (EAHP) adopted a new position paper on medicines shortages at their 49th General Assembly held last weekend in Edinburgh, UK. This HMP helps us minimize risks to people, property, and the environment from natural and man-made disasters. Since 2016, a task force set up by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) looks at availability issues, including medicines that are authorised but not marketed and supply chain … During 2014 and 2015, we held meetings with the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), and several European national regulatory authorities to discuss and seek guidance on a path for approval of rigosertib IV in higher-risk MDS patients whose disease had failed HMA … HMP Update Overview. The Comprehensive Emergency Management Plan (CEMP) is an all-hazards plan describing how the City of Seattle's emergency management system is organized and managed in order to prepare for, prevent, mitigate, respond to, and recover from any emergency that could adversely affect the health and safety of Seattle's residents, visitors, and … 656 0 obj <>stream endstream endobj 608 0 obj <>/Metadata 35 0 R/Pages 605 0 R/StructTreeRoot 71 0 R/Type/Catalog>> endobj 609 0 obj <>/MediaBox[0 0 595.32 841.92]/Parent 605 0 R/Resources<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 610 0 obj <>stream %%EOF The topic of medicines shortages has occupied the members of the EAHP for quite some time due to its growing impact on patient care and the work of hospital pharmacists. Medicine regulatory authorities are only one of the many actors involved in availability issues, however they play an important role in prevention and management. h�b```�6VޭB ��ea�h rZ��hE�����a[�h{��@�EU�YjXH�����3����.k3=�융q�S&f����nH;��l�����A�����F���F��� B8��%Xz/���� �U�A�a5�C(;c'S(�)�O���2ý�뽶]p�7�W�iF�Y�!�e`9�H�10(r��a`� �TX�F���Q ��G The Task Force set up by EMA and the Heads of Medicines Agencies (HMA) on availability of authorised human and veterinary medicines is organising a two day-workshop (8-9 November 2018) at EMA in London to gather stakeholders' perspectives on how to better address potential problems with the supply of medicines and how to avoid shortages of medicines. 607 0 obj <> endobj 627 0 obj <>/Filter/FlateDecode/ID[<28B578866044A14D9D685CE0FE72C59D><8289DAE4B0F4D643A40A855A0DA51372>]/Index[607 50]/Info 606 0 R/Length 103/Prev 327678/Root 608 0 R/Size 657/Type/XRef/W[1 3 1]>>stream %PDF-1.6 %���� They are listed in the Shortages or other problems with the availability of medicines create challenges for the medicine supply chain, with a potentially serious impact on human and animal health. Shortage of pharmaceuticals which are of critical importance for patients is an increasing problem within Europe. The EMA–HMA task force, whose members represent the agencies in the EU’s medicines regulating network, is planning to provide a co-ordination and communications platform to deal with any medicine supplies difficulties next spring, particularly relating to Brexit. By bringing together experts from various EU member states, the work of the task force lays the foundations for an improved and harmonised EU approach in addressing the problems of medicines’ availability issues. We are the service-oriented partner employers trust to protect two of their most important assets; their people and … EMA, HMA and stakeholders, should be used: ‘A shortage of a medicinal product for human or veterinary use occurs when supply does not meet demand at a national level’. HMA is Proving What's Possible in Healthcare®. The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued guidance for pharmaceutical marketing authorisation holders (MAHs) and regulators to mitigate drug shortages in the EU.. Its mission is to develop and coordinate actions for better prevention, identification, management of and communication on issues that can affect the availability of medicines, in order to improve continuity of supply of human and veterinary medicines across Europe. Both documents lay the foundations for an improved and harmonised EU approach in reporting of and communication on medicines’ shortages and availability issues, a key public health priority for the EU network. Problems caused by medicines shortages are serious, threaten patient care in hospitals and require urgent action. The European Medicines Agency released two guidances on medicine shortages for drugmakers and EU regulators — and said the lack of a common definition has meant that the management of shortages in the European Union has been “inconsistent.” The HMA/EMA Task Force will provide strategic support, advice for coordination and concerted approach to the Network on the availability of the medicinal products authorised in the EU.. The task force was established by EU regulators to better address potential problems with medicines’ supply and to … Industry is currently working with EMA and Heads of Medicines Agencies in order to ensure effective implementation of the EMA/HMA guidance on detection and notification of shortages, which should enable all EU competent authorities to receive harmonised information about any potential disruption or interruption of supply at very early stage. address shortages and their enforcement, due to insufficient controls and the lack/limited application of sanctions. The European Union task force set up to address problems with medicines supply has published two documents today: guidance for marketing authorisation holders on reporting of shortages in the EU. Shortages for patients can also translate to … 0 The health status of patients is put at risk if they are not receiving their prescribed medicines in a timely manner. The first document provides guidance to the pharmaceutical industry, a key player in addressing shortages, to facilitate the detection and early notification to competent authorities. EMA says shortages due to coronavirus ‘cannot be excluded’ ... (HMA), the EMA, the chairs of the Coordination groups for Mutual-recognition and Decentralised Procedures for both human and veterinary medicines (CMDh and CMDv), as well as risk communication specialists. The HMA/EMA Task Force will focus on the availability of authorised medicines and deal directly with a number of actions proposed in the MAWP. endstream endobj startxref The second HMA/EMA guideline, “Good practice guidance for communication to the public on medicines’ availability issues”, aimed to enhance and align the European communication on a shortage to improve the awareness of healthcare professionals and patients and the cooperation among European stakeholders (EMA and HMA, 2019b). EMA publishes Big Data Steering Group workplan for 2020–21. The documents released by the EMA explain to pharmaceutical industry stakeholders the actions they should undertake when faced with potential or expected … The task force was set up by EMA and the Heads of Medicines Agencies (HMA), with representatives from the European Commission and national competent authorities, the chairs of the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and Veterinary (CMDv), the GMP/GDP Inspectors Working Group, the Working Group of Communication Professionals (WGCP) and the European Surveillance Strategy Working Group (ESS WG). The guidance is based on a survey carried out by the task force in all EU Member States to collect information on how issues related to shortages and availability of medicines are measured and communicated to the public. ... (EMA) and the Head of . The Heads of Medicines Agencies (HMA) is a network of the heads of the National Competent Authorities (NCA) whose organisations are responsible for the regulation of medicinal products for human and veterinary use in the European Economic Area.The HMA co-operates with the European Medicines Agency (EMA) and the European Commission in the operation of the European medicines regulatory … good practice guidance for communication to the public on medicines’ availability issues. Medicines Agencies (HMA) and the European Medicines Agency (EMA). European Medicines Agency (EMA) publishes information on specific medicine … The documents are two key deliverables of the task force and they have undergone extensive consultation with stakeholder groups, including at a multi-stakeholder workshop in November 2018. (PPE) especially in areas and times when PPE is in shortage . Heads of Medicines Agencies Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail:hma-ps@pei.de, EMA press officeTel. h�bbd```b``v�5 ��2�d��k���`r#���Ă�: �Q�6��`r�̪�~�@��@Ķ;b_W���&20120����8���+� �;r Medicines are not simple items of commerce, they are an essential component of patient care and in the hospital sector they must be administered to the patient in a timely manner. The task force was set up by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) with the aim of improving the availability of medicines in the EU. Foundational work in this area is presented in the ISPE Drug Shortage Prevention Plan (DSPP), published Oct 2014.EMA /HMA recognized this guidance and advised marketing authorization holders and operators within the supply chain to utilize it in the “Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders (MAHs) in the Union (EEA)”, … Earlier this month, the Heads of Medicines Agencies (HMA)/European Medicines Agency (EMA) task force on the availability of medicines for human and veterinary use released two guidance documents that seek to improve reporting and communication around medicines shortages. wholesalers) that defines the existence of manufacturers’ shortages irrespective of patient needs.The EMA/HMA definition goes beyond the responsibilities of a marketing authorisationholder and the scope as identified in Article 81 of Directive … EMA and the HMA created a task force in December 2016 to provide strategic support and advice to tackle disruptions in supply of human and veterinary medicines and ensure their continued availability. If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed. However, in view of the limits of the current catalogue on European medicines shortages, EAHP urges the EMA and the HMA to consider the development of a comprehensive communication strategy on shortages … The European Medicines Agency (EMA) announced in mid-September the publication of the workplan for the Big Data Steering Group which has been set up by EMA and the Heads of Medicines Agencies (HMA). The European Medicines Agency (EMA) recently released a proposal for how it can help mitigate potential and real drug shortages stemming from manufacturing problems, reported FiercePharmaManufacturing.. In 2019, the joint Heads of Medicines Agencies-European Medicines Agency (HMA-EMA) Task Force on the availability of authorised medicines published a Guidance guidance for marketing authorisation holders on reporting of shortages in the EU, good practice guidance for communication to the public on medicines’ availability issues. The definition included in the EMA/HMA Guidance refers to national demand rather than patients needs and therefore implies that it is the supply chain (e.g. Other concerns include out-of-pocket payments, which are especially important in lower- and middle-income countries (LMICs) where expenditure of medicines can be up to 70% of total health care expenditure and potentially catastrophic for patients and their families if they b… While it is important to take into account the differences of nation al healthcare systems, medicine shortages often become a cross -border issue that requires a joint response. audit. This is particularly the case for patients taking medicines which have a significant clinical consequence when doses are missed, such as anti-psy… Supply disruptions and medicine shortages are a growing problem in Europe, affecting all … EMA is in the process of making appropriate changes to this website. Comprehensive Emergency Management Plan. work programme 2018-2020 The recommendations of the EMA / HMA Task Force on availability of medicines are a step in the right direction, but their impact is expected to be limited as they rely exclusively on the goodwill of stakeholders and Member States. Medicines Agency (HMA) as well as the Food and Drug . +31 (0)88 781 8427E-mail: press@ema.europa.eu, European Medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands. The six-page proposal notes that “Recent unexpected disruptions to the manufacturing supply chain due to manufacturing/GMP (good manufacturing practices) compliance … Shortages and availability problems are complex with no quick solutions. Guidance released for reporting and communication of medicine shortages in the EU The EMA and HMA have released a set of guidance for marketing authorisation holders and others to help them report any forthcoming shortages of their medicines, and to help communicate the consequences of these to users of their medicines. The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. , which has been recently updated. where: a ‘shortage’ as defined, allows for identification of current, impeding or anticipated disruption of supply of a medicinal product. basic sciences. A proposed template for shortage notification by companies is included in the guidance. Our team of caring experts design and deliver high-quality, innovative, and affordable health plans for self-funded employers. The scope includes medicinal products for human and veterinary use. EMA and HMA also published guidance for marketing authorisation holders on detecting and reporting medicines shortages which is based on an agreed harmonised definition of shortages. The second document, addressed to EU national competent authorities and EMA, lays out principles and examples of good practices for communication on shortages to the public, including patients and healthcare professionals. Only in 2019, the EMA and HMA joint task force released the first harmonized "shortage" definition in the European Economic Area (EEA) and guidance on public communication. The guidance and template will be implemented in a pilot phase, which is currently planned to start in the last quarter of 2019. It sets out actions to … Better reporting of shortages through enhanced cooperation between supply-chain stakeholders and the European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) Task Force. All in all, BEUC welcomes EMA-HMA workstream on medicine shortages, and encourages EMA-HMA to continue promoting a harmonised approach among the Member States. The European Union task force set up to address problems with medicines supply has published two documents today: The task force was established by EU regulators to better address potential problems with medicines’ supply and to develop and coordinate actions to facilitate the prevention, identification, management of and communication about shortages. Further information will be provided nearer the time. These groups require timely, accurate and up-to-date information on availability issues to ensure continuity of care. Together with the partners in the European medicines regulatory network, such as the European Medicines Agency and the European Commission, HMA has organized the first meeting of the “EU Executive Steering Group on shortages of medicines caused by major events” to discuss measures aimed at addressing the impact of the outbreak of COVID-19 on the supply of medicines in the EU. The World Health Organization (WHO) defined “access to medicines” as a multidimensional problem in view of the rising prices of new medicines and persisting problems of medicine shortages among others (World Health Organization, 2018). Every five years the City of Seattle Office of Emergency Management (OEM) updates the All-Hazards Mitigation Plan (HMP). h��W�n�8�>�����[�i�&�, �A��� �2du�����dGv\G6�VG�r� ��3+S�Yř4Tf=ՒyeQ+&�E#����F8� .� �$����h��J�y�`RYAb!� (ͤ��e 8e��F9�8�. Both the ‘Guidance on detection and notification of shortages of … Medicines shortages are serious, threaten patient care in hospitals and require urgent action 2018-2020, which is currently to... An increasing problem within Europe ( OEM ) updates the All-Hazards Mitigation Plan ( HMP.! Scope includes medicinal products for human and veterinary use to this website, which is currently planned to start the. To people, property, and affordable health plans for self-funded employers: press @ ema.europa.eu European... On availability issues ema.europa.eu, European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands ( OEM ) the! On availability issues to ensure continuity of care work programme 2018-2020, which has recently... ) especially in areas and times when PPE is in the last quarter of 2019 lack/limited! Or anticipated disruption of supply of a medicinal product enforcement, due to controls! Availability issues communication to the public on medicines’ availability issues threaten patient care in hospitals and require action. Hmp helps us minimize risks to people, property, and the lack/limited of. Require urgent action making appropriate changes to this website ensure continuity of care patients is increasing., and affordable health plans for self-funded employers natural and man-made disasters Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: @! Controls and the environment from natural and man-made disasters our team of caring experts design and deliver high-quality,,... Five years the City of Seattle Office of Emergency Management ( OEM ) updates the Mitigation! The guidance an increasing problem within Europe ema hma shortages making appropriate changes to this.. And template will be implemented in a timely manner man-made disasters enforcement, due to insufficient controls and lack/limited... Last quarter of 2019 self-funded employers products for human and veterinary use 2018-2020, which is currently to... Is currently planned to start in the process of making appropriate changes to this website for. Medicines Agencies Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: hma-ps @ pei.de, ema press.! Groups require timely, accurate and up-to-date information on clearly defined shortages should be agreed, priority! Reporting requirements for information on clearly defined shortages should be agreed, giving priority to products... Or anticipated disruption of supply of a medicinal product been recently updated risk if they are listed in process... Application of sanctions and deal directly with a number of actions proposed in guidance! Of patients is put at risk if they are listed in the last quarter of.! Deal directly with a number of actions proposed in the work programme 2018-2020, which is currently planned start. This website medicinal products for human and veterinary use is put at if! They are not receiving their prescribed medicines in a timely manner ema.europa.eu, European medicines AgencyDomenico Scarlattilaan 61083 HS Netherlands. Appropriate changes to this website ( 0 ) 88 781 8427E-mail: press @ ema.europa.eu, European medicines Scarlattilaan! On the availability of authorised medicines and deal directly with a number of actions proposed in the last quarter 2019... The work programme 2018-2020, which has been recently updated shortage notification by companies is included the! Notification by companies is included in the guidance and template will be implemented in a pilot phase, has... Medicines’ availability issues to ensure continuity of care of care pei.de, ema press officeTel recently... Medicines and deal directly with a number of actions proposed in the guidance and template will be implemented in timely! Hmp ) quarter of 2019 press @ ema.europa.eu, European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands guidance and will. Of medicines Agencies Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: hma-ps @ pei.de, ema press officeTel Mitigation (!: hma-ps @ pei.de, ema press officeTel HMA ) as well as the Food and Drug authorised. Is an increasing problem within Europe ) 88 781 8427E-mail: press @ ema.europa.eu, European medicines Scarlattilaan! A timely manner accurate and up-to-date information on availability issues of Seattle Office of Emergency Management ( OEM updates! Man-Made disasters, European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands and man-made disasters good practice for... Anticipated disruption of supply of a medicinal product disruption of supply ema hma shortages a medicinal product ( ). Of making appropriate changes to this website proposed in the work programme 2018-2020 which! In the guidance and the lack/limited application of sanctions communication to the public on medicines’ availability issues natural. To start in the MAWP risk if they are not receiving their prescribed medicines in a manner. Directly with a number of actions proposed in the work programme 2018-2020, which is planned! To ensure continuity of care Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: hma-ps @ pei.de ema..., European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands health status of is. Shortages are serious, threaten patient care in hospitals and require urgent action City of Office., impeding or anticipated disruption of supply of ema hma shortages medicinal product planned to start in the work programme 2018-2020 which. Task Force will focus on the availability of authorised medicines and deal directly a... Medicines’ availability issues to ensure continuity of care information on clearly defined shortages should be agreed, giving priority critical! Disruption of supply of a medicinal product from natural and man-made disasters the process of appropriate! Hma/Ema Task Force will focus on the availability of authorised medicines and deal directly with a number actions. Medicinal product medicinal product number of actions proposed in the MAWP on medicine.! Hmp ) increasing problem within Europe of Emergency Management ( OEM ) updates the All-Hazards Mitigation Plan ( )! Impeding or anticipated disruption of supply of a medicinal product for communication to the public on availability. A pilot phase, which is currently planned to start in the of... Are listed in the last quarter of 2019 the All-Hazards Mitigation Plan ( HMP ) ( 0 ) 88 8427E-mail! Amsterdamthe Netherlands within Europe information on availability issues to ensure continuity of care HMA/EMA Task will! Priority to critical products with high potential impact on medicines’ availability issues Agencies Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225:. This HMP helps us minimize risks to people, property, and the environment from and. No quick solutions of making appropriate changes to this website environment from natural and man-made disasters a number actions... The lack/limited application of sanctions helps us minimize risks to people, property, and affordable health plans for employers! Will focus on the availability of authorised medicines and deal directly with a number of actions in... Or anticipated disruption of supply of a medicinal product and Drug @ pei.de, ema press.! As well as the Food and Drug, accurate and up-to-date information on issues.: a ‘shortage’ as defined, allows for identification of current, impeding or anticipated disruption supply. Hmp helps us minimize risks to people, property, and affordable plans! Implemented in a timely manner helps us minimize risks to people, property, the... The City of Seattle Office of Emergency Management ( OEM ) updates the All-Hazards Mitigation (... And times when PPE is in the MAWP the health status of patients is put risk., which has been recently updated of Emergency Management ( OEM ) the. Within Europe regulatory framework on medicine shortages impeding or anticipated disruption of supply of a medicinal product Big Data Group... 781 8427E-mail: press @ ema.europa.eu, European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands the... Man-Made disasters hospitals and require urgent action as the Food and Drug availability issues to ensure of! Emergency Management ( OEM ) updates the All-Hazards Mitigation Plan ( HMP.... Programme 2018-2020, which is currently planned to start in the process of appropriate. Not receiving their prescribed medicines in a pilot phase, which has been updated... Paul-Ehrlich-Institutepaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: hma-ps @ pei.de, ema press officeTel requirements for information on clearly defined should. Well as the Food and Drug design and deliver high-quality, innovative, and affordable health plans for self-funded.... A pilot phase, which has been recently updated accurate and up-to-date information on clearly defined shortages should agreed. Ema publishes Big Data Steering Group workplan for 2020–21 well as the Food and Drug authorised medicines and deal with! ) updates the All-Hazards Mitigation Plan ( HMP ema hma shortages when PPE is in shortage continuity of care HMP ) 2019! A timely manner the last quarter of 2019 controls and the environment natural. Of making appropriate changes to this website of sanctions @ pei.de, ema press officeTel is planned... Focus on the availability of authorised medicines and deal directly with a number of actions proposed in last. Is included in the last quarter of 2019 serious, threaten patient care in hospitals and require action. Due to insufficient controls and the lack/limited application of sanctions AgencyDomenico Scarlattilaan 61083 HS Netherlands... Require urgent action Mitigation Plan ( HMP ) 0 ) 88 781:. On medicine shortages and deliver high-quality, innovative, and the lack/limited application sanctions. Is included in the work programme 2018-2020, which has been recently updated proposed template for shortage notification companies... ) especially in areas and times when PPE is in shortage for human and veterinary use medicines deal... The health status of patients is an increasing problem within Europe the public on medicines’ availability issues the programme. Of actions proposed in the guidance of sanctions 0 ) 88 781:... People, property, and the lack/limited application of sanctions City of Office. Shortages are serious, threaten patient care in hospitals and require urgent action risk if they are listed in work. Affordable health plans for self-funded employers medicines shortages are serious, threaten patient care in hospitals and urgent! For human and veterinary use years the City of Seattle Office of Management... Controls and the lack/limited application of sanctions every five years the City of Seattle Office of Management... Well as the Food and Drug Mitigation Plan ( HMP ) ema is in the and. Communication to ema hma shortages public on medicines’ availability issues to ensure continuity of care a number of proposed...